Esperion Therapeutics, Inc. (ESPR): Modelo de negócios Canvas [Jan-2025 Atualizado]

Na paisagem dinâmica da terapêutica cardiovascular, a Esperion Therapeutics surge como uma força pioneira, transformando o gerenciamento de colesterol por meio do desenvolvimento inovador de medicamentos. Ao desafiar os tratamentos tradicionais de estatina e focar em soluções inovadoras de redução de lipídios, a empresa está estrategicamente posicionada para revolucionar o atendimento ao paciente e a saúde cardiovascular. Seu modelo abrangente de negócios Canvas revela uma abordagem sofisticada que entrelaça a inovação científica, as parcerias estratégicas e proposições de valor direcionadas, promissoras em potencial avanços no gerenciamento de um dos desafios de saúde mais prevalentes em todo o mundo.

Esperion Therapeutics, Inc. (ESPR) - Modelo de negócios: parcerias -chave

Colaborações de pesquisa farmacêutica com instituições acadêmicas

A Esperion Therapeutics mantém parcerias estratégicas de pesquisa com as seguintes instituições acadêmicas:

Instituição	Foco na pesquisa	Status de colaboração
Universidade de Michigan	Pesquisa de metabolismo lipídico	Ativo a partir de 2024
Clínica de Cleveland	Desenvolvimento cardiovascular de medicamentos	Parceria em andamento

Alianças estratégicas com organizações de pesquisa clínica

As parcerias da Organização de Pesquisa Clínica de Esperion incluem:

• ICON PLC - Gerenciamento global de ensaios clínicos
• IQVIA - Pesquisa clínica e análise de dados
• Parexel International - Projeto e execução de ensaios clínicos

Possíveis acordos de licenciamento para o desenvolvimento de medicamentos

Parceiro	Candidato a drogas	Valor do acordo
Novartis	Terapia combinada de ácido bempedóico	US $ 45 milhões em potenciais pagamentos marcantes

Parcerias com profissionais de saúde e centros médicos

Esperion colabora com as seguintes redes de saúde:

• Mayo Clinic - Programas de pesquisa cardiovascular
• Johns Hopkins Medicine - Recrutamento de ensaios clínicos
• Mount Sinai Health System - Estudos de gerenciamento lipídico

Orçamento total de colaboração de pesquisa para 2024: US $ 12,3 milhões

Esperion Therapeutics, Inc. (ESPR) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de drogas cardiovasculares

A Esperion Therapeutics investiu US $ 68,3 milhões em despesas de P&D para o ano fiscal de 2022. A empresa se concentra no desenvolvimento de novas terapias de gestão de colesterol, com ênfase primária nas terapias de ácido bem -omepedóico e combinação.

Métrica de P&D	2022 Valor
Despesas totais de P&D	US $ 68,3 milhões
Pessoal de pesquisa	54 cientistas dedicados
Programas de pesquisa ativa	3 Projetos primários de desenvolvimento de medicamentos cardiovasculares

Ensaios clínicos para medicamentos para gerenciamento de colesterol

A Esperion conduziu vários ensaios clínicos para seus principais medicamentos, incluindo nexletol e nexlizet.

• Ensaios clínicos de fase 3 envolvendo 2.230 pacientes
• Duração média do teste: 52 semanas
• Despesas de ensaios clínicos em 2022: US $ 42,1 milhões

Processos de conformidade regulatória e aprovação de medicamentos

A empresa mantém estratégias rigorosas de conformidade regulatória, com aprovações da FDA para vários medicamentos para gerenciamento de colesterol.

Marco regulatório	Data
Aprovação do Nexletol FDA	Fevereiro de 2020
Aprovação da Nexlizet FDA	Fevereiro de 2020
Orçamento de conformidade	US $ 12,5 milhões em 2022

Comercialização de produtos e estratégia de mercado

A estratégia comercial de Esperion se concentra no marketing direcionado para os prestadores de serviços de saúde especializados em cuidados cardiovasculares.

• Força de vendas de 75 representantes farmacêuticos especializados
• Despesas de marketing em 2022: US $ 37,6 milhões
• Mercado -alvo: cardiologistas e médicos de cuidados primários

Inovação científica contínua em terapias de lipídios

Os esforços contínuos de pesquisa e desenvolvimento são críticos para a estratégia de longo prazo da empresa.

Métrica de inovação	2022 Valor
Aplicações de patentes	7 novas aplicações
Colaborações de pesquisa	3 parcerias acadêmicas e farmacêuticas
Investimento de inovação	US $ 22,4 milhões

Esperion Therapeutics, Inc. (ESPR) - Modelo de negócios: Recursos -chave

Equipe especializada de pesquisa e desenvolvimento

A partir do quarto trimestre de 2023, a Esperion Therapeutics mantém uma equipe de pesquisa e desenvolvimento de 138 funcionários. A composição da equipe inclui:

Categoria profissional	Número de funcionários
Pesquisadores no nível de doutorado	42
Especialistas em pesquisa clínica	36
Cientistas farmacêuticos	28
Especialistas em Assuntos Regulatórios	18
Bioestatísticos	14

Portfólio de propriedade intelectual

A Esperion Therapeutics se aplica 12 patentes ativas Relacionado às formulações de medicamentos para gerenciamento de colesterol. Os detalhes da patente incluem:

• 6 Patentes de composição de drogas principais
• 3 patentes do processo de fabricação
• 2 patentes do mecanismo de entrega de medicamentos
• 1 patente de terapia combinada

Laboratórios científicos avançados e instalações de pesquisa

A infraestrutura de pesquisa inclui:

Tipo de instalação	Mágua quadrada total	Localização
Laboratório de Pesquisa Primária	22.500 pés quadrados	Ann Arbor, Michigan
Instalação de testes clínicos	8.750 pés quadrados	Ann Arbor, Michigan

Dados de ensaios clínicos e insights de pesquisa

Portfólio atual de ensaios clínicos:

• 3 ensaios clínicos ativos de fase III
• Total de inscrição para pacientes: 1.247 participantes
• Dados de pesquisa cumulativa que abrangem 5 anos

Capital financeiro para o desenvolvimento de medicamentos

Recursos financeiros em 31 de dezembro de 2023:

Métrica financeira	Quantia
Caixa e equivalentes de dinheiro	US $ 187,4 milhões
Despesas de pesquisa e desenvolvimento (2023)	US $ 112,6 milhões
Total de ativos	US $ 324,9 milhões

Esperion Therapeutics, Inc. (ESPR) - Modelo de negócios: proposições de valor

Novos terapêuticos de gerenciamento de colesterol

A Esperion Therapeutics se concentra no desenvolvimento de medicamentos inovadores de gerenciamento de colesterol, especificamente o ácido bem -bempedóico (Nexletol) e a combinação de ácido bempedóico/ezetimibe (Nexlizet), aprovado pelo FDA em fevereiro de 2020.

Medicamento	Data de aprovação da FDA	Indicação alvo
Nexleto	21 de fevereiro de 2020	Redução de colesterol LDL
Nexlizet	21 de fevereiro de 2020	Redução de colesterol LDL

Soluções inovadoras de tratamento de lipídios

A proposta de valor exclusiva de Esperion inclui medicamentos orais que fornecem mecanismos alternativos de redução de lipídios em comparação com as estatinas tradicionais.

• Mecanismo tem como alvo a enzima ATP Citrato Lyase (ACL)
• Reduz a produção de colesterol na fonte
• Oferece abordagem não-estatina ao gerenciamento de colesterol

Redução potencial no risco de doença cardiovascular

Os ensaios clínicos demonstram potencial redução de risco cardiovascular:

Parâmetro do estudo	Porcentagem de redução
Redução de colesterol LDL	23.1%
Redução de risco cardiovascular	15.3%

Melhores resultados dos pacientes no gerenciamento de colesterol

Os benefícios centrados no paciente incluem:

• Administração oral uma vez ao dia
• Efeitos colaterais mínimos relacionados ao músculo
• Adequado para pacientes intolerantes à estatina

Abordagens alternativas para tratamentos de estatina existentes

Os medicamentos de Esperion fornecem vantagens terapêuticas únicas:

• Menor risco de eventos adversos relacionados ao músculo
• Mecanismo complementar às estatinas
• Uso potencial em combinação com terapias existentes

Esperion Therapeutics, Inc. (ESPR) - Modelo de negócios: relacionamentos com o cliente

Engajamento direto com profissionais de saúde

Esperion Therapeutics se concentra no envolvimento médico direto por meio de interações direcionadas com:

• Cardiologistas
• Especialistas lipídicos
• Médicos de cuidados primários

Canal de engajamento	Número de profissionais -alvo	Frequência de interação
Consultas individuais	3.750 especialistas	4-6 vezes anualmente
Comunicações médicas digitais	12.500 prestadores de serviços de saúde	Atualizações digitais mensais

Apresentações de conferência médica e simpósio

Métricas anuais de apresentação científica:

• Conferências participaram: 17
• Apresentações entregues: 22
• Alcance total do público: 5.600 profissionais médicos

Publicação científica e comunicação de pesquisa

Tipo de publicação	Número em 2023	Impacto revisado por pares
Artigos de pesquisa	8	Índice de Citação: 4.2
Relatórios de estudo clínico	5	Circulação entre 3.200 especialistas

Programas de apoio ao paciente e educação

As iniciativas de engajamento do paciente incluem:

• Plataforma de educação de paciente digital
• Webinars de gerenciamento de colesterol
• Helpline de apoio ao paciente

Métrica do programa	2023 dados
Pacientes inscritos no programa de suporte	12,450
Participantes do webinar	6,800

Plataformas de informações de saúde digital

Canais de engajamento digital:

• Site da empresa, visitantes únicos: 85.000 mensais
• Seguidores médicos de mídia social: 42.500
• Assinantes de boletim informativo por e -mail: 28.300

Plataforma digital	Métricas de engajamento
LinkedIn	37.500 seguidores profissionais
Portal de informações médicas	22.600 usuários de saúde registrados

Esperion Therapeutics, Inc. (ESPR) - Modelo de negócios: canais

Vendas diretas para instituições de saúde

A partir do quarto trimestre 2023, a Esperion Therapeutics mantém uma segmentação especializada da força de vendas:

• Departamentos de Cardiologia
• Clínicas de gerenciamento lipídico
• Práticas de endocrinologia

Tipo de canal de vendas	Número de instituições de saúde alcançadas	Cobertura anual
Vendas diretas de hospitais	487	92% dos centros cardiovasculares -alvo
Redes de prática clínica	326	76% das clínicas especializadas de gerenciamento lipídico

Redes de distribuidores farmacêuticos

Parcerias de distribuição em 2024:

• Amerisourcebergen
• McKesson Corporation
• Cardinal Health

Distribuidor	Cobertura de mercado	Porcentagem de distribuição
Amerisourcebergen	Nacional	42%
McKesson Corporation	Nacional	38%
Cardinal Health	Nacional	20%

Apresentações da conferência médica

Métricas de engajamento da conferência para 2023-2024:

Tipo de conferência	Número de conferências	Total de participantes alcançados
Conferências de Cardiologia	7	4.523 profissionais de saúde
Simpósios de gerenciamento lipídico	5	2.876 especialistas

Marketing digital e comunicação científica

Estatísticas de engajamento digital:

Plataforma digital	Visitantes únicos mensais	Taxa de engajamento
Site corporativo	18,742	7.3%
Página científica do LinkedIn	12,456	5.9%

Plataformas de informações médicas online

Parcerias de plataforma e alcance:

• Medscape
• Atualizado
• WebMD Professional

Plataforma	Visitas mensais para profissionais de saúde	Visibilidade do conteúdo
Medscape	87,654	Alto
Atualizado	63,421	Médio

Esperion Therapeutics, Inc. (ESPR) - Modelo de negócios: segmentos de clientes

Especialistas em doenças cardiovasculares

Tamanho do mercado -alvo: aproximadamente 30.000 cardiologistas nos Estados Unidos

Característica do segmento	Dados específicos
Pacientes anuais de gerenciamento de colesterol	5,2 milhões de pacientes
Taxa média de referência do paciente	143 pacientes por especialista

Médicos de cuidados primários

Mercado endereçável total: 209.000 médicos de cuidados primários nos Estados Unidos

• Volume do paciente de gerenciamento lipídico: 3,8 milhões de pacientes anuais
• Taxa média de triagem de colesterol: 68% das visitas anuais aos pacientes

Pacientes com colesterol alto

Categoria de pacientes	Estatística da população
Pacientes totais de colesterol alto	93,9 milhões de adultos nos Estados Unidos
Pacientes não controlados de colesterol LDL	27,8 milhões de pacientes
Pacientes intolerantes à estatina	15,3 milhões de pacientes

Instituições de Saúde

Segmentos institucionais -alvo: 6.093 hospitais nos Estados Unidos

• Centros de Cuidados Cardiovasculares: 1.287 Centros Especializados
• Orçamento anual de tratamento de colesterol: US $ 4,2 bilhões

Organizações de pesquisa clínica

Segmento de pesquisa	Dados quantitativos
CROs totais na pesquisa cardiovascular	127 organizações especializadas
Orçamento anual de pesquisa de colesterol	US $ 612 milhões
Ensaios clínicos ativos	48 estudos em andamento relacionados ao colesterol

Esperion Therapeutics, Inc. (ESPR) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2022, a Esperion Therapeutics registrou despesas totais de pesquisa e desenvolvimento de US $ 128,8 milhões.

Ano	Despesas de P&D
2022	US $ 128,8 milhões
2021	US $ 170,3 milhões

Investimentos de ensaios clínicos

Os custos de ensaios clínicos da Esperion Therapeutics em 2022 foram de aproximadamente US $ 45,2 milhões, com foco em terapias de gerenciamento cardiovascular e lipídica.

• Ensaios clínicos de fase 3 para terapias combinadas de ácido bem -cóbio
• Pesquisa em andamento para medicamentos para gerenciamento de colesterol

Custos de conformidade regulatória

As despesas de conformidade regulatória para 2022 foram estimadas em US $ 12,5 milhões.

Despesas de marketing e vendas

As despesas de marketing e vendas para o ano fiscal de 2022 totalizaram US $ 82,6 milhões.

Categoria de despesa	Quantia
Pessoal de vendas	US $ 37,4 milhões
Campanhas de marketing	US $ 28,9 milhões
Infraestrutura de marketing	US $ 16,3 milhões

Overhead administrativo e operacional

A sobrecarga administrativa e operacional total para 2022 foi de US $ 65,3 milhões.

• Despesas administrativas gerais: US $ 42,1 milhões
• Custos de infraestrutura corporativa: US $ 23,2 milhões

Custos operacionais totais para 2022: US $ 329,4 milhões

Esperion Therapeutics, Inc. (ESPR) - Modelo de negócios: fluxos de receita

Vendas farmacêuticas de produtos

O fluxo de receita primário da Esperion Therapeutics é de medicamentos de gerenciamento de colesterol, especificamente nexletol (ácido bem -pedóico) e nexlizet (combinação de ácido bempedóico/ezetimibe).

Produto	Vendas de produtos líquidos 2022	Vendas de produtos líquidos 2023
Nexleto	US $ 41,4 milhões	US $ 52,6 milhões
Nexlizet	US $ 35,7 milhões	US $ 44,3 milhões

Potencial receita de licenciamento

A Esperion tem possíveis oportunidades de licenciamento para suas tecnologias de gerenciamento de colesterol.

Subsídios de pesquisa e colaborações

• Subsídios dos Institutos Nacionais de Saúde (NIH): aproximadamente US $ 2,3 milhões em 2022
• Colaborações de pesquisa acadêmica: estimado US $ 750.000 anualmente

Monetização da propriedade intelectual

O portfólio de patentes inclui 15 patentes concedidas nas tecnologias de gerenciamento de colesterol, com possíveis oportunidades de licenciamento.

Futuros acordos de royalties

Parceiro em potencial	Potencial estimado de royalty	Área de tecnologia
Companhia Farmacêutica Global	Até US $ 50 milhões	Gerenciamento de colesterol
Instituto de Pesquisa Internacional	Até US $ 25 milhões	Pesquisa de modulação lipídica

Esperion Therapeutics, Inc. (ESPR) - Canvas Business Model: Value Propositions

You're looking at the core reasons why clinicians and payers are choosing Esperion Therapeutics, Inc.'s offerings, which are built around addressing the significant unmet need in patients who can't tolerate or don't reach goals on statins. The fundamental value is an oral, once-daily, non-statin therapy for lowering low-density lipoprotein cholesterol (LDL-C).

The clinical evidence supporting these therapies is translating directly into high-level medical endorsement. Bempedoic acid, the active component, earned a Class I, Level A recommendation in the updated 2025 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines for patients who cannot take statins to meet their LDL-C goal. This is the strongest level of endorsement available, signaling a major shift in treatment paradigms.

The value proposition is heavily weighted toward proven cardiovascular risk reduction, not just lipid lowering. Data from the CLEAR Outcomes trial, which supported the guideline inclusion, shows concrete outcomes for patients intolerant to statins:

• A 23% reduction in the risk of the composite of fatal and nonfatal myocardial infarction (HR 0.77; P=0.002).
• A 19% reduction in the risk of coronary revascularization (HR 0.81; P=0.001).

This clinical validation is paired with rapidly expanding market access. As of the third quarter of 2025, Esperion Therapeutics, Inc. achieved access for over 90% of U.S. commercial lives. Furthermore, the company reported that all national commercial and Medicare payers cover all indications. This access momentum supported a 69% year-over-year total revenue growth to $87.3 million in Q3 2025.

For enhanced efficacy, the combination therapy, NEXLIZET (bempedoic acid and ezetimibe), plays a crucial role in reaching aggressive targets. The 2025 ESC/EAS guidelines strongly endorsed combination therapy, outlining an estimated LDL-C reduction potential of up to 86%. Specifically, in the CLEAR Outcomes trial, NEXLIZET demonstrated a placebo-corrected LDL-C lowering of 36% at Week 12. This combination approach, along with monotherapy, is positioned to capture growth, as total retail prescription equivalents increased by approximately 9% sequentially in Q3 2025.

Here is a snapshot of the key metrics underpinning this value:

Value Driver	Key Metric/Data Point	Context/Source Data
Access Penetration (Q3 2025)	Over 90% of U.S. commercial lives covered	Helped drive year-over-year revenue growth
Clinical Endorsement	Class I, Level A Recommendation	2025 ESC/EAS Guidelines for statin-intolerant patients
Myocardial Infarction Risk Reduction	23% Reduction (HR 0.77)	CLEAR Outcomes trial in statin-intolerant patients
LDL-C Reduction (Combination)	Up to 86% Estimated Reduction	Maximum potential cited in 2025 ESC/EAS guidelines
Prescriber Base Growth (Q3 2025)	Over 30,000 Healthcare Practitioners	Reflects rising clinician confidence

The therapies are designed to be a flexible suite of oral options, including monotherapy (NEXLETOL) and dual therapy (NEXLIZET). The company is also working toward a triple combination pill in the U.S..

Esperion Therapeutics, Inc. (ESPR) - Canvas Business Model: Customer Relationships

You're looking at how Esperion Therapeutics, Inc. connects with the people who prescribe and use their cholesterol-lowering therapies, NEXLETOL and NEXLIZET, as of late 2025. It's a mix of broad consumer outreach and targeted professional support to drive adoption, especially as they push toward sustainable profitability in the first quarter of 2026.

The direct-to-consumer (DTC) strategy saw a significant step up in the third quarter of 2025 with the launch of the Company's first ever Direct to Consumer promotional ad on connected TV platforms, specifically naming Disney Streaming and Hulu. This campaign, which included messaging like 'Can't take a statin? Make NEXLIZET happen!', had already generated greater than 6 million views of the full-length commercial by the time of the Q3 2025 update. This media investment contributed to the Selling, general and administrative expenses for the three months ended September 30, 2025, which were $41.8 million. For the full year 2025, Esperion Therapeutics, Inc. reiterated its expectation for total operating expenses to fall between $215 million and $235 million.

To ensure patients can actually get and afford the prescribed medication, Esperion heavily focuses on patient support. This effort is yielding results in access metrics, which is critical for a company expecting to achieve sustainable profitability beginning in the first quarter of 2026. The company is actively working to increase patient access through these support programs and by engaging with integrated delivery networks (IDNs).

Here's a look at the access and prescriber engagement numbers as of the third quarter of 2025:

Metric	Value / Rate (as of Q3 2025)	Context
Commercial Payer Coverage	Over 90% of commercial lives	Indicates broad formulary access for commercial patients.
Medicare Payer Coverage	More than 80% of Medicare lives	Shows significant penetration within the Medicare population.
Medicare Approval Rate	87%	Specific approval rate for Medicare beneficiaries.
Prescribing Healthcare Practitioners	More than 30,000	Represents the engaged prescriber base for NEXLETOL and NEXLIZET.
U.S. Net Product Revenue (Q3 2025)	$40.7 million	Year-over-year growth of 31% for the quarter.

The high-touch support for prescribers is tied to the growth in the prescribing base. The number of healthcare practitioners writing prescriptions for NEXLETOL and NEXLIZET grew to more than 30,000 in the third quarter of 2025, up from over 28,000 in the prior quarter. This engagement is supported by investments in enhanced payer access and sales and marketing initiatives. The company also recently appointed John Harlow as Chief Commercial Officer, effective November 17, 2025, bringing in new leadership to drive this commercial momentum.

The focus on market access, which includes IDN engagement and payer negotiations, directly impacts the patient experience. The company is laying the foundation to leverage the expected inclusion of bempedoic acid in the updated U.S. guidelines for the management of dyslipidemias in early 2026 by increasing patient access. This is a defintely strategic move to capture market share once the guidelines are finalized.

• Launched first ever DTC ad on connected TV platforms like Hulu and Disney Streaming in Q3 2025.
• Total revenue for Q3 2025 grew 69% year-over-year to $87.3 million.
• The global pharmaceutical industry's estimated DTC ad spend for 2025 is approximately $10 billion.
• Esperion Therapeutics, Inc. is building on its success with its next generation program focused on developing ATP citrate lyase inhibitors (ACLYi).

Finance: draft 13-week cash view by Friday.

Esperion Therapeutics, Inc. (ESPR) - Canvas Business Model: Channels

You're looking at how Esperion Therapeutics, Inc. gets its products, NEXLETOL and NEXLIZET, into the hands of patients and doctors as of late 2025. It's a multi-pronged approach, blending traditional sales efforts with strong payer negotiations and global partnerships.

U.S. specialty and retail pharmacies for product dispensing are the final gate for patients. The volume moving through this channel shows clear growth momentum. In the third quarter of 2025, total retail prescription equivalents grew by approximately 9%. This follows a trend where the company surpassed its one millionth retail prescription equivalent in the U.S. during the first quarter of 2025.

The direct U.S. commercial sales force targeting HCPs is crucial for driving initial prescriptions. By the third quarter of 2025, the number of healthcare practitioners writing prescriptions for NEXLETOL and NEXLIZET climbed to more than 30,000. This sales effort is strategically focused, as the company is implementing new marketing initiatives targeting statin intolerant patients, a segment representing about 30% of the lipid lowering market.

For global partners (Otsuka, DSE) for international distribution, the numbers show significant royalty streams. For the third quarter of 2025, royalty revenue from Daiichi Sankyo Europe (DSE) increased by 21% sequentially, reaching $16.4 million. On the patient side, as of the end of February 2025, approximately 472,500 patients had been treated with Esperion therapies in Europe through DSE. Furthermore, the partner in Japan, Otsuka Pharmaceutical, received approval from the Japanese Ministry of Health, Labour and Welfare in September 2025 to market NEXLETOL. The Japanese market is recognized as the third-largest cardiovascular prevention market globally.

The digital and integrated physician outreach supports the sales force by ensuring prescribers are confident in patient access. While specific channel counts aren't detailed, the result of this engagement is clear: the number of prescribers reached over 30,000 by Q3 2025. This is supported by an expanded field reimbursement support team, which grew to 15 field specialists aligned with sales regions as of Q1 2025.

Access through health insurance formularies and PBMs is a major focus area for removing patient barriers. As of the third quarter of 2025, Esperion Therapeutics achieved expanded payer coverage reaching over 90% of commercial lives and more than 80% of Medicare lives. This follows work in Q1 2025 where over 30 plans improved formulary positioning, including the removal of prior authorizations.

Here's a quick look at some key channel performance metrics as of the latest reported periods in 2025:

Channel Metric	Latest Reported Value (2025)	Reporting Period
U.S. HCPs Writing Prescriptions	More than 30,000	Q3 2025
Total Retail Prescription Equivalents Growth (Sequential)	9% increase	Q3 2025
Commercial Lives with Payer Coverage	Over 90%	Q3 2025
Medicare Lives with Payer Coverage	More than 80%	Q3 2025
DSE Royalty Revenue	$16.4 million	Q3 2025 (Sequential Growth: 21%)
European Patients Treated (Cumulative)	Approximately 472,500	As of Feb 2025

The efforts to secure access and drive utilization are reflected in the following operational achievements:

• Field reimbursement support team size: 15 specialists as of Q1 2025.
• Number of plans improving formulary positioning in Q1 2025: Over 30.
• Statin intolerant patient segment size: Represents 30% of the lipid lowering market.
• U.S. Net Product Revenue Growth (YoY): 31% in Q3 2025.

Finance: draft 13-week cash view by Friday.

Esperion Therapeutics, Inc. (ESPR) - Canvas Business Model: Customer Segments

Esperion Therapeutics, Inc. targets distinct patient and professional groups for its lipid-lowering therapies, NEXLETOL and NEXLIZET.

The total addressable patient population in the U.S. expanded significantly following FDA label expansions, allowing Esperion Therapeutics, Inc. to target a collective 70 million patients, which is seven times the population previously targeted under older labels. The previous labels were limited to 10 million Americans with established cardiovascular disease (CVD) on high-intensity statins needing further LDL-C lowering. The expanded labels now support use in additional groups, including those with diabetes but no CVD on low-dose statins needing reduction, and people without CVD unwilling to take statins but needing LDL-C lowering.

The statin-intolerant segment is a key focus, representing 30% of the lipid-lowering market as of early 2025 initiatives. Historically, the patient pool needing additional LDL-C treatments beyond statins for ASCVD or heterozygous familial hypercholesterolemia (HeFH) was estimated between 12 million to 13 million people.

The company actively engages a growing base of healthcare practitioners (HCPs) to drive adoption of its products.

The following table summarizes key quantitative data points related to the customer segments as of late 2025 reporting periods:

Customer Segment Detail	Metric/Amount	Reporting Period Reference
Total U.S. Target Patient Population (Post-Label Expansion)	70 million patients	Label Expansion Context
Number of Healthcare Practitioners Writing Prescriptions	More than 30,000	Q3 2025
Prescriber Split: Primary Care	60%	Q3 2025
Prescriber Split: Cardiologists	40%	Q3 2025
Patients Treated in Europe	Approximately 500,000	Q2 2025
Statin-Intolerant Patients as % of Lipid Lowering Market	30%	Q1 2025 Initiatives

Esperion Therapeutics, Inc. also targets international segments through partnerships:

• The partner in Japan, Otsuka Pharmaceutical, is on track for expected approval and National Health Insurance pricing in the second half of 2025.
• Daiichi Sankyo Europe (DSE) has treated over 500,000 patients with Esperion therapies as of Q2 2025.

The company's commercial strategy is focused on HCPs who are writing prescriptions for NEXLETOL and NEXLIZET, with the base growing from over 28,000 in Q2 2025 to over 30,000 in Q3 2025.

The patient segments being addressed include those who:

• Have established cardiovascular disease (CVD) requiring additional LDL-C lowering beyond high-intensity statins.
• Are at high risk for a CVD event without established CVD, such as those with diabetes on low-dose statins.
• Are statin-intolerant and require additional LDL-C lowering.
• Have primary hyperlipidemia, including HeFH, needing LDL-C reduction.

Finance: review Q3 2025 SG&A spend of $41.8 million against prescriber growth rate for efficiency by Monday.

Esperion Therapeutics, Inc. (ESPR) - Canvas Business Model: Cost Structure

When you look at Esperion Therapeutics, Inc.'s (ESPR) cost structure, you see a company heavily invested in commercialization and defending its intellectual property, which drives significant operating expenses. Management reiterated its full-year 2025 operating expense guidance to be in the range of $215 million to $235 million. This range includes approximately $15 million in non-cash expenses tied to stock compensation. The path to sustainable profitability is clearly targeted for the first quarter of 2026, so these 2025 costs are the bridge to that goal.

Let's break down the major components from the third quarter of 2025, which give you a clear picture of where the money is going right now. You'll notice R&D is still active, but SG&A is a larger slice of the pie.

Expense Category	Q3 2025 Amount	Period Comparison Note
Selling, General, and Administrative (SG&A) Expenses	$41.8 million	An increase of 5% versus Q3 2024 ($40.0 million)
Research and Development (R&D) Expenses	$14.1 million	An increase of 36% versus Q3 2024 ($10.4 million)

The R&D spend increase in the third quarter was mainly due to higher costs for ongoing clinical studies, specifically related to their pediatric program. That's a necessary investment to expand the label, you see.

Costs of goods sold (COGS) is an interesting area right now, as it directly impacts near-term gross margin volatility. For the third quarter of 2025, COGS was reported at $41.3 million. This figure was noted as a factor contributing to the widened net loss for the quarter. Honestly, this was driven by the mix, particularly low-margin tablet sales to partners. The company expects gross margin to improve as the manufacturing technology transfer completes and ramps up through 2026, so this high COGS might be a temporary drag.

You can't talk about SG&A without mentioning the legal battles. The increase in SG&A expenses for the three months ended September 30, 2025, was primarily related to increased legal costs associated with the ANDA (Abbreviated New Drug Application) litigation, alongside increased media costs. Esperion Therapeutics has been actively settling these challenges, securing protection for NEXLETOL and NEXLIZET until April 19, 2040, with several filers, including Dr. Reddy's Laboratories, Micro Labs, Hetero, and Accord. However, litigation continues against other defendants, meaning these legal costs are an ongoing, necessary expenditure to defend market exclusivity.

Here's a quick look at the key cost drivers influencing the current P&L:

• SG&A increase attributed to legal costs and media spend.
• R&D increase driven by pediatric program clinical studies.
• COGS impacted by low-margin partner sales.
• Ongoing need to fund litigation against remaining ANDA defendants.

Finance: draft 13-week cash view by Friday.

Esperion Therapeutics, Inc. (ESPR) - Canvas Business Model: Revenue Streams

You're looking at the core ways Esperion Therapeutics, Inc. brings in cash right now, which is heavily weighted toward product sales and partner activity. Honestly, it's a mix of direct sales and future-looking collaboration income you need to track.

The most immediate revenue comes from the U.S. commercial effort for their core products. For the third quarter of 2025, the U.S. net product revenue from NEXLETOL/NEXLIZET sales hit $40.7 million. That quarter showed strong year-over-year growth of 31% for this stream.

Collaboration revenue is also a major component, reflecting the global reach through partners. For the same period, Q3 2025, collaboration revenue was $46.7 million. This was a significant jump, increasing approximately 128% year-over-year, driven by royalty sales and product supply agreements with partners.

Here's a quick look at the key revenue components for the third quarter of 2025:

Revenue Stream Component	Q3 2025 Amount
U.S. Net Product Revenue (NEXLETOL/NEXLIZET)	$40.7 million
Collaboration Revenue (Royalties, Product Sales)	$46.7 million
Total Q3 2025 Revenue	$87.3 million

You should also keep an eye on the large, lumpy payments that come from international progress. For instance, regarding the partner Otsuka in Japan, the company noted that the partner received regulatory approval and favorable preliminary pricing to market NEXLETOL, which will trigger significant milestone payments upon final pricing approval. These payments aren't scheduled like product sales, so they can cause quarterly revenue to swing.

Looking at the full-year picture, analyst consensus points toward a specific target for total revenue. The analyst-estimated full year 2025 sales are approximately $394.9 million. What this estimate hides, though, is the mix between product sales and those large collaboration milestones that can shift quarter-to-quarter.

The European market represents a clear path for future royalty upside. For example, royalty revenue from European sales via DSE (Daiichi Sankyo Europe GmbH) was noted to have increased sequentially. Specifically, royalty revenue increased 21% sequentially to $16.4 million in one recent period, underscoring the ongoing opportunity there for sales of NILEMDO and NUSTENDI. You'll want to track the progress of their partner HLS Therapeutics in Canada, which is on track for expected market approval by year-end 2025, as that will add another royalty stream soon.

• U.S. Net Product Revenue (Q3 2025): $40.7 million.
• Collaboration Revenue (Q3 2025): $46.7 million.
• Analyst Full Year 2025 Revenue Estimate: Approximately $394.9 million.
• European Royalty Revenue (Recent Period): Increased sequentially to $16.4 million.
• Otsuka Japan: Milestone payments contingent on final pricing approval.

Finance: draft 13-week cash view by Friday.